Skip to content

Analgesic, Sedative and Antibiotic Pharmacokinetics during Extracorporeal Membrane Oxygenation: Understanding altered pharmacokinetics to improve patient outcomes.

Pharmacokinetic modelling of antibiotic, sedative and analgesic drugs and their relevant metabolites in critically ill patients receiving extracorporeal membrane oxygenation (ECMO) and development of dosing guidelines to optimise drug therapy during ECMO.

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ANZCTR
Registry ID
ACTRN12612000559819
Acronym
ASAP-ECMO
Enrollment
160
Registered
2012-05-25
Start date
2011-11-04
Completion date
Unknown
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Critically ill patients may be temporarily placed on extracorporeal memebrane oxygenation (ECMO) machines to allow the heart and lungs to rest while the disease is treated with drugs. ECMO, together with severe illness, affects the way drugs work. This research aims to understand the combined effects of the ECMO circuit and severe illness on drug treatment. The results will allow us to develop guidelines to assist doctors in administering the right dose of the right drug at the right time to patients on ECMO.

Interventions

Patients will be eligible for recruitment any time during the ECMO run. Pharmacokinetic samples will be obtained as per the protocol when a new antibiotc ,sedative or analgesic drug is commenced or when an existing sedative or analgesic agent is discontinued by the treating clinician. Sedative and analgesic drugs: Sedative and analgesic drugs will be administered according to local policies at each ICU. As a guide, intravenous Infusions and boluses of morphine (10-30 mg/hr) and midazolam (10-30

Patients will be eligible for recruitment any time during the ECMO run. Pharmacokinetic samples will be obtained as per the protocol when a new antibiotc ,sedative or analgesic drug is commenced or when an existing sedative or analgesic agent is discontinued by the treating clinician. Sedative and analgesic drugs: Sedative and analgesic drugs will be administered according to local policies at each ICU. As a guide, intravenous Infusions and boluses of morphine (10-30 mg/hr) and midazolam (10-30 mg/hr) titrated to a Richmond Agitation Sedation Scale (RASS) of -3 to -4 and a bispectral index (BIS) of 40-45. Patient ventilator interactions may also be used as a guide to titrate sedation especially in patients on venovenous ECMO. Therapeutic paralysis is at the discretion of the treating clinician and will be guided by neuromuscular monitoring. Additional intravenous sedation if required may be provided with one of the following agents: 1. Propofol (10-200 mg/hr) 2. Dexmeditomedine (1 mcg/kg bolus and 0.1 -1.5 mcg/kg/min) 3. Fentanyl (50-300 mcg/hour) if morphine is discontinued for clinical reasons. 4. Thiopentone ( 100-200 mg/hour)* * Note- Thiopentone is uncommonly used as an ultimate rescue sedative in some patients on ECMO Antibiotics: Antibiotic drug selection and dosing will be at the discretion of the clinician, based on the clinical context and unit guidelines. Doses will be reconstituted in 10 ml of diluent and given as bolus infusion in 50 ml over 30 minutes (except ciprofloxacin and vancomycin – 1-2 hour infusion), or as per local hospital protocols. Sample collection Blood samples will be drawn from an existing arterial line and collected in 2 ml tubes with Lithium Heparin anticoagulant. It is recommended that a closed loop Venous Arterial blood Management Protection system (VAMP, Edward Life sciences, Canada Inc) be used to minimise blood loss during sampling. Minimum sample volume is 2 mls per time point. Another 0.5 mls of blood will be drawn for each additional drug studied. It is unlikely for a patient to be receiving more than 4 study drugs at a given time during PK sampling. Labels and collection tubes will be provided. Sedatives and analgesics: General PK sampling Blood samples will be taken from an existing arterial line at 0, 15, 30, 45, 60, 120, 180, 240, 360 minutes on commencement or cessation of a new sedative drug infusion. Details of drugs, doses and rates of administration to be documented on the data sheet. Antibiotics: All patients will be sampled over a single dosing period during ECMO treatment. Where two or more antibiotics of interest are prescribed for one patient, collect data on timing of administration for both drugs accurately and sample according to the antibiotic with the longer dosing interval. For example vancomycin 1g q12h and piperacillin 4.5g q6h; sample according to the vancomycin 12-hourly dosing schedule. 1. Six-hourly dosing schedule – Blood will be sampled from an existing arterial line at the following time points 0, 15, 30, 45, 60, 90, 120, 180 and 360 minutes. 2. Eight or 12-hourly dosing schedule – Blood samples will be collected from an existing arterial line at the following time points 0, 15, 30, 45, 60, 90, 120, 180 and 480 minutes. Urine specimens: Creatinine clearance for patients not receiving renal replacement therapy: An 8- hour urinary creatinine clearance collection will be obtained and assayed by the local pathology service to determine glomerular filtration rate. For patients receiving RRT the type and dose of the treatment will be documented on the data sheet.

Sponsors

Critical Care Research Group
Lead SponsorOther Collaborative groups

Eligibility

Sex/Gender
All
Age
18 Years to 89 Years
Healthy volunteers
No

Inclusion criteria

- Currently undergoing ECMO for respiratory +/- cardiac dysfunction - Clinical indication for the antibiotics ceftriaxone, cefepime, meropenem, gentamicin, ciprofloxacin, ticarcillin-clavulanate, piperacillin-tazobactum, vancomycin, linezolid, caspofungin, fluconazole, voriconazole and oseltamivir - Clinical indication for the sedatives and analgesics morphine, fentanyl, midazolam, dexmedetomidine, propfol or thiopentone

Exclusion criteria

- No valid consent - Known allergy to study drug - Pregnancy - S. Bilirubin >150 - Ongoing massive blood loss and blood product transfusion - Therapeutic plasma exchange in the last 24 hours.

Outcome results

None listed

Source: ANZCTR · Data processed: Mar 25, 2026